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Abstract
Background: The aim was to identify novel diagnostic autoantibody candidates for rheumatoid arthritis (RA) by
comprehensive screening for autoreactivity.
Method: We incubated 5892 recombinant proteins coupled to fluorescent beads, with patients’ sera for the detection
of IgG-autoantibodies in three independent patient cohorts: A (n = 72 patients with established RA); B/B- (n = 116
patients with early RA (B) and n = 51 CCP-negative patients with early RA from B (B-)); and C (n = 184 patients with
early seronegative RA), in comparison to matched healthy controls. Intersects of significantly increased autoantibodies
as determined by the Mann-Whitney test were sought.
Result: Screening of 5892 antigens in RA cohorts A and B, or the seronegative cohorts B- and C revealed
intersects of 23 and 13 significantly increased autoantibodies, respectively. Reactivity to three antigens was
increased in all cohorts tested: N-acetylglucosamine-1-phosphate transferase, gamma subunit (GNPTG), heterogeneous
nuclear ribonucleoprotein A1-like 2 (HNRNPA1), and insulin-like growth factor binding protein 2 (IGFBP2).
Conclusions: Comprehensive sequential screening for autoantibodies reveals novel candidates for diagnostic markers
in both seropositive and seronegative RA and suggests new fields of research into the pathogenesis of RA.
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Background
Rheumatoid arthritis (RA) is a chronic inflammatory auto-
immune disease characterized by destruction of cartilage
and bone. RA pathogenesis features numerous auto-
immune processes such as autoreactive T cells and the for-
mation of autoantibodies [1]. Amongst the autoantibodies
present in RA sera, rheumatoid factor (RF) and antibodies
against citrullinated peptides (ACPA) have emerged as im-
portant diagnostic and prognostic markers [2], although a
range of other autoantibodies have been identified [3].
Evidence is accumulating that RF and ACPA are directly
involved in the pathogenesis of the disease [4], potentially
even prior to the occurrence of synovial inflammation [5].
Despite progress in the serologic diagnosis of RA intro-
duced by the detection of these antibodies, a considerable
number of patients with RA do not display RF and/or
ACPA [6, 7]. In these cases, the diagnosis of RA relies
heavily upon clinical presentation and imaging proce-
dures. Thus, identification of reliable additional markers
to recognize RF/ACPA-negative RA and to further ascer-
tain the diagnosis of RF/ACPA-positive RA is desirable.
We adopted a multiplex bead-based approach to se-
quentially screen sera from three independent patient
cohorts: cohort A, patients with established RA; cohort B,
patients with early RA; and cohort C, patients with sero-
negative RA) for the presence of autoantibodies to over
5800 human antigens, aiming to (1) retrieve a collection
of candidates for future diagnostic assay development, and
(2) gain new insights into the pathogenesis of RA.
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Methods
Sample cohorts and autoantibody identification strategy
In order to identify potential novel diagnostic autoanti-
bodies, antibody profiles of serum samples from different
RA patient cohorts were sequentially compared to healthy
controls. Healthy controls were chosen in an age-adjusted
and sex-adjusted manner from specimens from blood do-
nors of the Bavarian Red Cross, Germany or collected
from healthy individuals after the exclusion of rheumatic
diseases from a community screening program. Patient
cohorts were as follows. Cohort A (established RA)
comprised 72 consecutive patients with established RA
according to American College of Rheumatology (ACR)/
European League Against Rheumatism (EULAR) 2010 cri-
teria (age 56.1 ± 13.3 years, 73.6 % female, Disease Activity
Score for 28 joints (DAS28) 3.5 ± 2.3, therapy: methotrex-
ate 40 %, leflunomide 12.5 %, tumor necrosis factor alpha
(TNFa)-blockade 18 %) from the outpatient department
of Heinrich-Heine-University Düsseldorf. These patients
were compared to 71 age-matched and sex-matched
healthy controls (age 54.6 ± 11.3 years, 73.2 % female).
Cohort B (early RA) comprised 116 patients with early
RA from the HIT HARD study [8] (age 49.8 ± 13.8 years,
71.3 % female, DAS28 6.1 ± 1.0, all therapy-naive). These
patients were compared to 116 healthy controls (age
49.8 ± 12.8 years, 71.6 % female). A subgroup analysis
was conducted in seronegative patients from cohort B,
termed B- (n = 51, age 54.5 ± 13.3 years, 66 % female).
Cohort C (seronegative cohort) comprised 184 patients
with ACPA-negative RA according to 2010 ACR/EULAR
criteria (age 60.2 ± 13.8 years, 62.5 % % female, all therapy-
naive). These patients were compared to 184 healthy
controls (age 55.2 ± 10 years, 62.5 % female). All serum
samples were obtained by standard procedures and
stored at -80 °C until use.
Multiplex bead-based autoantibody detection
We produced 5892 recombinant antigens in Escherichia
coli and purified them. Five cDNA libraries originating
from different human tissues (fetal brain, colon, lung,
liver, Cd4 induced and non-induced T cells) were used
for the recombinant production of human antigens. All
of these cDNA libraries were oligo(dT)-primed, contain-
ing the coding region for an N-terminally located hexa-
histidine-tag and were under transcriptional control of
the lactose inducible promoter from E. coli [9]. Sequence
integrity of the cDNA libraries was confirmed by 5’
DNA sequencing. Additionally, expression clones repre-
senting the full-length sequence derived from the human
ORFeome collection [10] were included. Individual anti-
gens were designed in silico, synthesized chemically (Life
Technologies, Carlsbad, USA) and cloned into the ex-
pression vector pQE30-NST fused to the coding region
for the N-terminal-located His6-tag. Of the antigens,
73 % were produced by cDNA library expression clones,
24 % of the antigens derive from clones of the human
ORFeome collection and 3 % of the antigens were based
on in silico design.
Recombinant gene expression was performed in E. coli
SCS1 cells carrying plasmid pSE111 for improved ex-
pression of human genes [11]. Cells were cultivated in
200 ml auto-induction medium (Overnight Express auto-
induction medium, Merck, Darmstadt, Germany) overnight
and harvested by centrifugation. Bacterial pellets were lysed
by resuspension in 15 ml lysis buffer (6 M guanidinium-
HCl, 0.1 M NaH2PO4, 0.01 M Tris-HCl, pH 8.0). Soluble
proteins were affinity-purified after binding to Protino®
Ni-IDA 1000 Funnel Column (Macherey-Nagel, Düren,
Germany). Columns were washed with 8 ml washing
buffer (8 M urea, 0.1 M NaH2PO4, 0.01 M Tris-HCl,
pH 6.3). Proteins were eluted in 3 ml elution buffer
(6 M urea, 0.1 M NaH2PO4, 0.01 M Tris-HCl, 0.5 %
(w/v) trehalose pH 4.5). Each protein preparation was
transferred into 2D-barcoded tubes, lyophilized and
stored at -20 °C.
In this study, twenty different bead-based arrays contain-
ing up to 384 different proteins were used. For production
of bead-based arrays (BBA), the proteins were coupled to
magnetic carboxylated color-coded beads (MagPlex™
microspheres, Luminex Corporation, Austin, TX, USA).
The manufacturer’s protocol for coupling proteins to
MagPlex™ microspheres was adapted to use liquid hand-
ling systems. A semi-automated coupling procedure of
one BBA encompassed 384 single, separate coupling reac-
tions, which were carried out in four 96-well plates. For
each single coupling reaction, up to 12.5 μg antigen and
8.8 × 105 MagPlex™ beads of one color region (ID) were
used. All liquid handling steps were carried out by either
an eight-channel pipetting system (Starlet, Hamilton
Robotics, Bonaduz, Switzerland) or a 96-channel pipet-
ting system (Evo Freedom 150, Tecan, Männderdorf,
Switzerland). For semi-automated coupling, antigens
were dissolved in H2O, and aliquots of 60 microliters
were transferred from 2D barcode tubes to 96-well
plates. MagPlex™ microspheres were homogeneously re-
suspended and each bead ID was transferred in one
well of a 96-well plate. The 96-well plates containing
the microspheres were placed on a magnetic separator
(LifeSep™, Dexter Magnetic Technologies Inc., Elk Grove
Village, USA) to sediment the beads for washing steps and
on a microtiter plate shaker (MTS2/4, IKA) to facilitate
permanent mixing for incubation steps.
For coupling, the microspheres were washed three
times with activation buffer (100 mM NaH2PO4, pH 6.2)
and resuspended in 120 μl activation buffer. To obtain
reactive sulfo-NHS-ester intermediates, 15 μl 1-ethly-3-
(3-dimethlyaminopropyl) carbodiimide (50 mg/ml) and
15 μl N-hydroxy-succinimide (50 mg/ml) were applied
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to microspheres. After 20 minutes incubation (900 rpm,
room temperature (RT)) the microspheres were washed
three times with coupling buffer (50 mM MES, pH 5.0)
and resuspended in 65 μl coupling buffer. Immediately,
60 μl antigen solution was added to reactive microspheres
and coupling took place over 120 minutes under perman-
ent mixing (900 rpm, RT). After three wash cycles using
washing buffer (PBS, 0.1 % Tween20) coupled beads were
resuspended in blocking buffer (PBS, 1 % BSA, 0.05 %
ProClin300), incubated for 20 minutes (900 rpm, RT) and
then transferred to be maintained at 4–8 °C for 12–72 h.
To monitor the assay performance various proteins
were used as control proteins and coupled individually
to microspheres as described for antigens. Human and
mouse IgG (Sigma-Aldrich, St. Louis, USA) were used to
control the reactivity of the detection antibodies, BSA
(Sigma-Aldrich) to monitor the background and E. coli
lysate to detect serum antibodies directed against E. coli
proteins. For coupling reaction control 10 μg, 25 μg,
100 μg and 200 μg human IgG, 200 μg mouse IgG, 1 μg
BSA and 500 μg E. coli proteins were used, respectively.
A bead mix of a multiplex BBA was generated by pooling
384 antigen-coupled beads together with control protein-
coupled beads. The BBA was stored at 4–8 °C until use.
Serum samples were transferred to 2D barcode tubes
and a 1:100 serum dilution was prepared with assay buf-
fer (PBS, 0.5 % BSA, 10 % E. coli lysate, 50 % Low-Cross
buffer (Candor Technologies, Nürnberg, Germany)) in
96-well plates. The serum dilutions were first incubated
for 20 minutes to neutralize any human IgG eventually
directed against E. coli proteins. The BBA was sonicated
for 5 minutes and the bead mix was distributed in
96-well plates. After three wash cycles with washing
buffer (PBS, 0.05 % Tween20) serum dilutions (50 μl)
were added to the bead mix and incubated for 20 h
(900 rpm, 4–8 °C). Supernatants were removed from the
beads by three wash cycles, and secondary R-phycoerythrin-
labeled antibody (5 μg/ml, goat anti-human, Dianova,
Hamburg, Germany) was added for a final incubation
of 45 minutes (900 rpm, RT). The beads were washed three
times with washing buffer (PBS, 0.1 % Tween20) and re-
suspended in 100 μl sheath fluid (Luminex Corporation).
Subsequently, beads were analyzed in a FlexMap3D device
for fluorescent signal readout (DD gate 7.500–15.000; sam-
ple size: 80 μl; 1000 events per bead ID; timeout 60 sec).
The binding events were displayed as median fluorescence
intensity (MFI). Measurements were disregarded when low
numbers of bead events (<30 beads) were counted per
bead ID.
Statistical analysis
Our antigen prioritization approach was sequential per-
formance of the Mann-Whitney test to identify intersects
of significantly upregulated markers in the patient cohorts
compared to matched healthy controls. For data pre-
processing and normalization, if fewer than 30 beads
were counted for a specific antigen, the corresponding
MFI value was set to missing. Samples or antigens were
discarded from further analysis if either a patient sam-
ple or an antigen had >20 % missing values. In total, six
patients and 1.5 % of antigens tested were discarded be-
cause of >20 % missing values. Prior to normalization,
MFI values were log2-transformed. Quantile normalization
was used to normalize data on each individual plate by
BBA according to [12]. A missing MFI value for an antigen
was replaced by the respective median value across all sam-
ples for this specific antigen. Replacement of the data by
median imputed values was necessary for <0.25 % without
notable accumulation in certain antigens. The target vari-
able for all statistical work was the MFI of the detection
antibody.
Antigens with an upregulated MFI and fold change ≥1
were further considered. The fold change was calculated
as the ratio of median MFI of cases vs. controls. In each
cohort, receiver operating characteristic (ROC) analyses
were subsequently applied to calculate sensitivity at
predefined 90 % specificity in comparison to respective
matched healthy controls. The statistical software R
(version 2.14.2 (2012-02-29)) [http://www.r-project.org]
was used for all analyses.
Results
Candidate autoantibody identification in patients with RA
Comparison of autoreactivity to 5892 antigens in sera from
72 patients with established RA (cohort A) and 116 therapy-
naive patients with early RA (cohort B) resulted in an inter-
sect of 23 antigens with an individual p value <0.05 and fold
change >1 (Fig. 1). Fold changes ranged from 1.1 to 2.7 as
detailed in Table 1.
Candidate autoantibody identification in seronegative
patients with RA
In order to more specifically assess autoantibodies in
seronegative RA, intersects of significantly increased
autoantibodies in the seronegative subgroup of cohort
B (termed B-) and an independent therapy-naïve cohort
of 184 seronegative patients with RA (cohort C) was sought,
resulting in 13 antigenic targets. Fold changes ranged from
1.1 to 1.8 as outlined in Table 2.
Candidate autoantibody identification in all cohorts
Significantly increased autoantibodies in all cohorts
were then identified resulting in diverse intersects as
shown in Fig. 1. Significantly increased autoantibodies
to three antigens were noted in all three cohorts (A, B
and C) with fold changes ranging from 1.1 to 1.5 as de-
tailed in Table 3.
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Discussion
In the current study, we set out to identify new diagnos-
tic markers in RA with the use of an extensive screening
for IgG autoantibodies. The strength of this study con-
sists in the comprehensive inclusion of a vast number of
potential autoantigens and the subsequent narrowing of
the candidate list, employing independent patient cohorts.
Importantly, cohorts B and C represented sera from
therapy-naïve patients with early RA, emphasizing the
potential significance of our results for early serological
diagnosis of the disease. Moreover, parts of the analyses
focused on seronegative patients, resulting in identifica-
tion of new interesting targets.
The risk of over-fitting the data is inherent in the
adopted discovery approach with consideration of over
5800 antigens. Larger patient numbers were restricted
due to practicability and cost considerations. Thus, we
concentrated on single antigen performance and had to
refrain from testing marker combinations. Furthermore,
correction for multiple testing would have rendered the
discovery approach unpromising a priori. Rather than
direct diagnostic implications, the reported antigens are
therefore considered attractive candidates, subject to im-
proved ELISA-based assay development and subsequent
clinical testing. The advantages of improved laboratory
diagnosis are evident, because 30 % of the RA patient
population cannot be identified applying diagnostic test-
ing for ACPA and/or rheumatoid factor (RF) [8].
We and others assume that a certain percentage of
seronegative patients are truly seronegative, i.e. do not
generate autoantibodies in the course of the disease,
whereas other patients have autoantibodies against so
far undisclosed antigens [13]. We further expect that this
group of false-negative seronegative patients is heteroge-
neous, and that detection of low-frequency autoantibodies
is required for serological detection. Only unmodified
antigens were tested and only IgG antibodies were con-
sidered in the current study. Modifications such as
citrullination and carbamylation [14] carry the potential
for better detection rates and may yet unmask a greater
proportion of seronegative patients with RA. However,
we chose to use non-modified proteins (i.e. without
citrullination, carbamylation or acetylation) as we follow
the hypothesis that RA may have several different patho-
physiological routes, of which the formation of autoanti-
bodies against post-translational modifications and protein
complexes is just one (major) route. We find support for
this hypothesis in the previous discovery of non-modified
antigens such as RA33 (HNRNPA2/B1) and 14-3-3
[15, 16]. Interestingly, 14-3-3 is an antigen both in un-
modified and in citrullinated form [17].
Similarly, we found vimentin in its native form (as
confirmed by tandem mass spectrometry) to be an auto-
antigen in both cohorts A and B [18], and vimentin is
known to be a major target of ACPA in its citrullinated
form [19]. We further assumed that novel autoantibodies
would most likely be present in smaller subsets of pa-
tients. Low prevalence is a common feature of autoanti-
bodies in other autoimmune diseases: in systemic sclerosis
several antigens have been described, which occur with a
prevalence between 5 and 10 % (Th/T0, U3RNP, PM/Scl)
[20], and in systemic lupus over 100 autoantibodies have
been published, many of which have a prevalence below
15 % [21]. This makes their discovery difficult, because the
ratio between high numbers of antigens used in omics-
type screening is already in imbalance to the number of
available patient samples. This imbalance is further com-
plicated if novel markers are present in only 5–15 % of
cases. Of note, in the present study, sensitivity of antigens
across all group comparisons at a predefined specificity of
90 % was 17.7 ± 7.5 %, ranging from 2 to 41 %. Even
though the study was designed to identify targets rather
than determine their individual diagnostic performance,
these results seem promising for individual diagnostic
assay development. Furthermore, future validation of
these diagnostic candidates should be carried out, ideally
in early RA and include disease controls such as psoriatic
arthritis.
Even though we used both established RA (cohorts A)
and early RA (cohort B and C) for marker identification
with the aim of identifying ubiquitous antigens in RA,
the use of more homogeneous cohorts (e.g. seronegative
patients only, or patients with early RA only) would
represent an alternative approach to antigenic target iden-
tification. Clearly, the population used for screening
Fig. 1 Intersects of significantly increased IgG-autoantibodies
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approaches largely influences the resulting candidates.
Thus, we maintain that an antibody identification
strategy by an omics-type approach should be regarded as
a means to reduce the number of potential individual tar-
gets. This in turn enables targeted individual autoantibody
validation studies. We found support for this approach in
other screening studies which similarly resulted in, albeit
different, sets of potential targets [13]. This is probably
due to different patient populations in terms of numbers
of patients and ethnicity, and differences in the autoanti-
body identification approach [13], amongst other reasons.
Nevertheless, all screening approaches result in potential
targets for further individual testing and carry the poten-
tial for future diagnostic improvements, as has elegantly
been demonstrated previously [13, 22].
After comprehensive screening of over 5800 antigens,
we describe 23 potential new diagnostic antigens in RA
and 13 for seronegative, early RA. As both currently used
diagnostic antibodies (e.g. RF and ACPA antibodies) are
involved in the pathogenesis of RA [4], it is interesting
to speculate which functionalities the newly identified
antigenic targets may have, as this might open up new
fields of research into the pathogenesis of RA.
Some of the antigens found have previously been
linked to RA. Of the three antigens identified in all groups,
increased levels of insulin-like growth factor binding pro-
tein 2 (IGFBP2) were found in sera from patients with RA,
and these correlate with CRP levels and were speculated to
contribute to catabolic states in RA [23]. Heterogeneous
nuclear ribonucleoprotein A1 (HNRNPA1) has previously
been associated with RA, systemic lupus erythemato-
sus and mixed connective tissue diseases and other
rheumatic diseases [15]. A clear connection between
N-acetylglucosamine-1-phosphate transferase (GNPTG)
and RA is so far unrecognized.
Of the antigens identified specifically in seronegative
cohorts, a pathophysiological connection to actin beta
(ACTB) is conclusive: autoreactive citrullinated epitopes
of beta actin have been identified in synovial fluid in RA
[24]. Moreover, pharmacological inhibition of actin
cytoskeleton dynamics influences the pathogenicity of
fibroblasts in arthritis [25]. A testable hypothesis would
Table 1 Intersect of significantly increased IgG-autoantibodies in patients with established RA (cohort A) and early RA (cohort B)
Antigen Cohort A Cohort B
symbol Name Gene ID P FC S P FC S
DCTN1 Dynactin 1 1639 0.026 1.5 14 0.001 1.5 19
GNPTG N-acetylglucosamine-1-phosphate transferase 84572 0.021 1.2 17 0.001 1.3 13
HNRNPA1 Heterogeneous nuclear ribonucleoprotein A1-like 2 144983 0.020 1.3 22 0.000 1.3 34
ITFG3 Integrin alpha FG-GAP repeat containing 3 83986 0.048 1.1 19 0.014 1.1 23
APOA4 Apolipoprotein A-IV 337 0.025 1.1 35 0.001 1.2 11
CCDC136 Coiled-coil domain containing 136 64753 0.039 2.2 14 0.031 1.7 2
CKAP4 Cytoskeleton-associated protein 4 10970 0.027 1.2 22 0.000 1.3 28
CLCN2 Chloride channel 2 1181 0.037 1.3 19 0.016 1.2 10
DMTF1 Cyclin D binding myb-like transcription factor 1 9988 0.047 1.3 22 0.022 1.3 11
FAM59B Family with sequence similarity 59. member B 150946 0.047 1.9 18 0.000 1.5 15
IGFBP2 Insulin-like growth factor binding protein 3485 0.015 1.2 19 0.000 1.5 13
TMCO7 Transmembrane and coiled-coil domains 7 79613 0.009 1.1 21 0.000 1.5 20
USP48 Ubiquitin specific peptidase 48 84196 0.001 2.7 18 0.034 1.7 11
VIM Vimentin 7431 0.022 1.3 19 0.000 1.7 38
ZFAND2B Zinc finger. AN1-type domain 2B 130617 0.034 1.2 18 0.002 1.3 22
ATP6V1A ATPase. H+ transporting. lysosomal 70 kDa. V1 subunit A 523 0.048 1.2 21 0.042 1.3 11
GSN Gelsolin 2934 0.008 1.4 26 0.001 1.4 12
GSPT2 G1 to S phase transition 2 23708 0.045 1.2 14 0.043 1.3 8
HSBP1 Heat shock factor binding protein 1 3281 0.021 1.2 25 0.002 1.3 19
NONO Non-POU domain containing. octamer-binding 4841 0.010 1.4 21 0.016 1.3 17
PRAP1 Proline-rich acidic protein 1 118471 0.030 1.3 14 0.035 1.6 9
YES1 YES proto-oncogene 1. Src family tyrosine kinase 6714 0.032 1.1 28 0.010 1.2 13
SSB Sjogren syndrome antigen B (autoantigen La) 6741 0.009 1.4 15 0.042 1.1 17
Cohort A: established rheumatoid arthritis (RA) (n = 72). Cohort B: early RA (n = 116). P is p value for fold change (FC) and sensitivity (S) at 90 % specificity
compared to matched healthy controls, according to the Mann-Whitney test
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thus be that autoantibodies to beta actin might alter
the cytoskeleton assembly and functionality of synovial
fibroblasts towards an RA phenotype. Further, plasma
kallikrein (antibodies to the beta subunit (KLKB1) were
identified) is part of a cascade that results in the activa-
tion of bradykinins, which are considered to be potent
inflammatory mediators with relevance in arthritis [26].
Of the intersecting antigens identified in the mixed co-
horts A and B, gelsolin (GSN) was recently identified as
a promising urinary biomarker for RA [27]. Increased
levels of apolipoprotein A4 (APOA4) have been identified
in sera from patients with RA using a proteomic approach
[28]. Decreased levels of proline-rich acidic proteins have
been identified in patients with RA reporting oral sicca
symptoms [29]. The roles of the respective antibodies, like
PRAP1-antibodies, have not been investigated in this re-
gard so far. Moreover, dynactin 1 (DCTN1) has been
shown to be an integral part of osteoclast formation and
function [30]. Finally, even though antibodies to SSB are a
hallmark of Sjögren’s syndrome, these antibodies are also
found in RA [31].
The identified antibodies to these known targets deserve
further functional studies to determine their potential role
in the pathogenesis of RA. Of note, most of the antigenic
targets identified have not been thoroughly investigated in
the context of RA and may thus open up new fields of re-
search. Future studies will adopt the challenge of large-
scale screening for post-translationally modified antigens,
and to assess the individual performance of the retrieved
candidates.
Conclusions
Comprehensive sequential autoantibody profiling revealed
novel, highly interesting, IgG-autoantibodies for future
diagnostic assay development and pathophysiological
research, especially in seronegative RA.
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